Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer

Key Points Question What are the prevalences of likely pathogenic or pathogenic (LP/P) germline variants in esophageal, gastroesophageal junction, and gastric cancers? Findings In this cross-sectional study of 515 patients, LP/P germline variants occurred in approximately one-fifth of patients with gastric cancer. Those with early-onset esophagogastic cancer (≤50 years of age at diagnosis) were significantly more likely to harbor an LP/P germline variant. Meaning The results of this study support germline testing in patients with gastric cancer and early-onset esophagogastric cancer.

[1]  B. Karlan,et al.  Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  F. Saad,et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[3]  A. Chen,et al.  Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[5]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[6]  M. Berger,et al.  Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms , 2018, Journal of the National Cancer Institute.

[7]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[8]  Raymond M. Moore,et al.  Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer , 2018, JAMA.

[9]  Zarina Shameer,et al.  Towards Automation of Germline Variant Curation in Clinical Cancer Genetics , 2018, Genetics in Medicine.

[10]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[11]  Benjamin J. Raphael,et al.  Integrated genomic characterization of oesophageal carcinoma , 2017, Nature.

[12]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[13]  Siân Jones,et al.  Prevalence of deleterious ATM germline mutations in gastric cancer patients , 2015, Oncotarget.

[14]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[15]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[16]  R. Seruca,et al.  Familial gastric cancer: genetic susceptibility, pathology, and implications for management. , 2015, The Lancet. Oncology.

[17]  R. Bennett,et al.  A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment , 2014, Genetics in Medicine.

[18]  G. Ku,et al.  Management of gastric cancer , 2014, Current opinion in gastroenterology.

[19]  Sofia Khan,et al.  Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations , 2012, Familial Cancer.

[20]  R. Scott,et al.  BRCA2 gene mutations in families with aggregations of breast and stomach cancers , 2002, British Journal of Cancer.

[21]  J. Klijn,et al.  ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. , 2000, American journal of human genetics.

[22]  Å. Borg,et al.  Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. , 1999, European journal of cancer.

[23]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.